Assertio Holdings, Inc.

Listed Company

ASRTCIK 0001808665NasdaqAcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$118.71M

Net Income

$-30.38M

Total Assets

$266.97M

Equity

$93.95M

Shares Out

6.45M

Op. Cash Flow

$-28.18M

Business

Assertio Holdings, Inc. is a pharmaceutical company that commercializes differentiated prescription drugs focused on oncology, neurology, and pain management. Its main products include ROLVEDON, Sympazan, Otrexup, SPRIX, INDOCIN, and CAMBIA, which the company licenses, acquires, markets and supports with patient/provider services. Business operations center on commercial capabilities with a direct sales force for ROLVEDON and an omni-channel promotional model (sales force, digital channels, virtual reps and ML) for Sympazan and other products. Products are sold primarily in the U.S. through national wholesale distributors to hospitals, outpatient clinics and pharmacies.

Summary from filing dated 2025-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	119	125	152	156	111
Cost of sales	35	39	27	19	16
Research and development expenses	2	4	3	0	—
Selling, general and administrative expenses	69	75	79	47	53
Change in fair value of contingent consideration	−276,000	−244,000	−26	19	4
Amortization of intangible assets	30	26	28	33	28
Impairment of intangible assets	2	5	—	—	—
Restructuring charges	3	720,000	5	0	1
Total costs and expenses	140	149	396	117	102
Loss from operations	−22	−24	−244	39	9
Loss on Assertio Therapeutics divestiture	−8	0	—	—	—
Interest expense	−3	−3	—	—	—
Interest income	3	3	2	—	—
Other gain, net	180,000	3	377,000	—	—
Total other (expense) income	−8	3	−11	−8	−10
Net loss before income taxes	−30	−22	−254	31	−553,000
Income tax expense	−400,000	−100,000	−78	79	−700,000
Net loss and comprehensive loss	−30	−22	−332	110	−1
Basic net loss per share (in dollars per share)	−4.74	−3.4	−4.67	2.33	−0.03
Diluted net loss per share (in dollars per share)	−4.74	−3.4	−4.67	2.03	−0.03
Shares used in computing basic net loss per share (in shares)	6	6	71	47	43
Shares used in computing diluted net loss per share (in shares)	6	6	71	55	43

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	10	51	73	65	37
Short-term investments	53	49	0	—	—
Accounts receivable, net	120	54	48	45	44
Inventories, net	24	38	38	14	7
Prepaid and other current assets	9	10	12	8	15
Total current assets	217	203	171	132	103
Property and equipment, net	444,000	586,000	770,000	744,000	2
Intangible assets, net	49	80	111	198	216
Other long-term assets	972,000	1	3	3	5
Total assets	267	285	286	414	327
Accounts payable	9	15	13	6	7
Accrued rebates, returns and discounts	99	76	58	49	53
Accrued liabilities	14	19	18	12	15
Contingent consideration, current portion	0	726,000	3	26	15
Other current liabilities	5	4	954,000	948,000	34
Total current liabilities	128	115	93	95	135
Long-term debt	39	39	39	66	61
Other long-term liabilities	6	10	16	4	5
Total liabilities	173	164	148	188	224
Commitments and contingencies (Note 8)	—	—	—	—	—
Common stock, $0.0001 par value, 200,000,000 shares authorized; 6,421,899 and 6,369,133 shares issued and outstanding as of December 31, 2025 and 2024, respectively	1,000	1,000	9,000	5,000	4,000
Additional paid-in capital	797	794	790	545	532
Accumulated deficit	−703	−673	−652	−320	−429
Total shareholders equity	94	121	138	226	102
Total liabilities and shareholders' equity	267	285	286	414	327

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	30	26	28	33	29
Amortization of debt issuance costs	475,000	439,000	—	—	—
Accretion of interest income from short-term investments	93,000	−542,000	0	—	—
Recurring fair value measurements of assets and liabilities	−435,000	−397,000	−25	19	4
Payment of contingent consideration	−450,000	−2	0	—	—
Stock-based compensation	3	5	9	8	4
Provisions for inventory	5	9	—	—	—
Accounts receivable	−66	−6	49	−996,000	−11,000
Inventories	10	−10	−5	−7	4
Prepaid and other assets	1	4	−1	8	4
Accounts payable and other accrued liabilities	−13	−1	−29	−10	−29
Accrued rebates, returns and discounts	23	18	−12	−3	−10
Net cash (used in) provided by operating activities	−28	26	50	79	6
Assertio Therapeutics divestiture	−8	0	—	—	—
Proceeds from maturities of short-term investments	115	50	0	—	—
Purchases of short-term investments	−119	−99	0	—	—
Net cash used in investing activities	−12	−49	3	−43	−19
Payments related to the vesting and settlement of equity awards, net	−189,000	−350,000	−8	−838,000	−418,000
Net cash used in financing activities	−189,000	−350,000	−44	−8	29
Net decrease in cash and cash equivalents	−40	−23	9	28	16
Cash paid for interest	3	3	4	8	10

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro